Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors

What's the purpose of this trial?

This study will test the safety, tolerability, and pharmacokinetics of VP301 in patients with relapsed or refractory multiple myeloma, lymphoma, or solid tumors.

This trial is currently open and accepting patients.


What will happen during the trial?

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

  • Histologic diagnosis of a refractory solid tumor, refractory myeloma or lymphoma with measurable or evaluable disease
  • Patients must have progressed following all therapies of known, potential clinical benefit, or for whom treatments of known clinical benefit are contraindicated.
  • Adequate kidney, liver, and hematologic function
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

Exclusion Criteria:

  • Active brain metastases and history of leptomeningeal metastases.
  • Myeloma patients with plasmacytoma as only measurable disease
  • Non-secretory myeloma
  • Patients with advanced metastatic, symptomatic, visceral spread who are at risk of life-threatening complications
  • Active or chronic, uncontrolled bacterial, viral, or fungal infection(s)
  • Abnormal ECG
  • Has clinically significant cardiovascular disease
  • Additional active malignancy that may confound the assessment of the study endpoints
  • Pregnancy or lactation
  • Known seropositivity for HIV (human immunodeficiency virus) or active hepatitis B or hepatitis C

Additional Trial Information

Phase 1

Enrollment: 110 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Texas

NEXT Oncology (San Antonio)

San Antonio, TX

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message